Sonic Healthcare Splits Managers on Its Margin Recovery Timeline

Fund managers disagree on whether regulatory pressure in Australia and Germany will delay Sonic's path back to stronger margins

22 Jun 2026 · 4 min read

Pathology giant Sonic Healthcare has spent the past year navigating post-COVID revenue normalisation, wage inflation and government reimbursement pressure, leaving fund managers split between calling the stock cheap and worrying the cheapness reflects real structural risk.

A COVID hangover meets wage inflation

Auscap Asset Management's September 2025 review captured the core tension: shares had recovered to around $28 from a low near $25, but the manager remained cautious given ongoing debate over how much of Sonic's pandemic-era COVID PCR testing revenue was genuinely temporary, alongside continuing wage inflation and labour shortages affecting pathologists and lab technicians. Infinity Asset Management's own September update showed the market's harsher read on the FY25 result: revenue grew 8 per cent and net profit grew just 0.5 per cent, a 7 per cent miss to consensus, with anatomical pathology growth in the US proving a particular problem despite strength in Australia, Germany and the UK.

A guidance reaffirmation sparks a rebound

The stock kept falling through October, down 23.4 per cent between August and October on earnings downgrades, before Infinity Asset Management reported a strong November rebound of 10.3 per cent following a positive AGM update. Management reaffirmed FY26 EBITDA guidance of A$1.87 billion to A$1.95 billion and guided to lower-than-expected depreciation and interest expense growth, improving the earnings outlook and raising the potential for net profit to exceed consensus forecasts.

Sonic Healthcare (SHL); rebounded strongly in November, rising 10.3% after a difficult prior three months in which the stock declined 23.4% amid earnings downgrades between August and October. The recovery was driven by a positive AGM trading update, where management reaffirmed FY26 EBITDA guidance of A$1.87-1.95bn.

— Infinity Asset Management, Monthly Report, November 2025

A defensive dividend yield draws new buyers

Ellerston Capital added Sonic as a new defensive holding in November 2025 after the sharp share price fall, citing a superior 4.7 per cent dividend yield, while Ten Cap added to its own position in March 2026, arguing recent weakness had created attractive entry points. Not everyone stayed the course: Oracle Advisory Group sold its position in December 2025 to fund other purchases, having originally added the stock only in April as an undervalued stalwart before cost inflation and below-inflation Medicare reimbursements produced a profit warning.

A split verdict on the margin recovery story

By May 2026, opinion had hardened into a genuine disagreement. Alliance Bernstein rated the stock a hold, intrigued by long-term blood testing demand growth but wary of the tension between rising volumes and government pressure to cut costs. Paradice Investment Management went further, rating it a sell on concerns that looming Australian and German budget decisions could extract further savings from the pathology sector, arguing the margin recovery story remained further away than consensus assumed, and noting Sonic's history of acquisitions had not yet demonstrated the free cash flow needed to prove long-term value creation.

We worry about the regulatory backdrop, especially for Australia and Germany. So with a budget looming next week, we worry there are potentially further savings the government is looking to extract from the pathology sector. So we think the margin recovery story is still some way out, and we worry that consensus looks a little high.

— Paradice Investment Management, Article, May 2026

A sale and leaseback frees up capital

Pendal Group's June 2026 update showed management taking its own steps to address the balance sheet, announcing a $445 million sale and leaseback of its Brisbane lab. Pendal noted this frees up capital without changing debt metrics under accounting rules, and would be around 1 per cent accretive to earnings if deployed into a buyback, though it suspected the company would prefer to use the proceeds for a deal instead.